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ABSTRACT
The safety and immunogenicity of a monovalent inactivated vaccine against Leptospira interrogans
serogroup Icterohaemorrhagiae was evaluated in 84 volunteers according to the route of administration,
i.e., subcutaneous (SC) or intramuscular (IM), in a double-blind randomised trial. The volunteers were
randomised into four groups: SC vaccine; IM vaccine; SC placebo; and IM placebo. Primary vaccination
comprised two injections on day 0 and day 14, with a booster after 6 months. A second booster was
given 30 months after primary vaccination. Local reactions within 1 h of injections were rare, with no
difference between vaccine groups. Local reactions within 3 h were more frequent after the second, third
and fourth SC injections than after IM injections. Systemic reactions never occurred within 1 h of
vaccination and were rare within 3 days; the rates were comparable for the different vaccine groups.
Evolution of the antibody responses, as assessed by microscopic agglutination tests and speciﬁc IgG and
IgM ELISAs, were similar for both injection routes. IgG seroconversion rates after the ﬁrst booster were
97% (95% CI 80–100%) for the SC vaccine group, and 96% (95% CI 80–100%) for the IM vaccine group,
and both reached 100% for IgG after the second booster. The safety and immunogenicity of the anti-
leptospiral vaccine were both good. Monitoring of antibody levels established that a booster dose
triggered a strong antibody response in fully vaccinated subjects at 30 months after primary vaccination.
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INTRODUCTION
Leptospirosis is a worldwide zoonosis caused by
a bacterium of the genus Leptospira [1,2]. Symp-
toms of leptospirosis appear c. 2 weeks after
infection, and comprise high fever, headaches,
chills, muscle pains, vomiting and, in some
cases, jaundice, abdominal pain and ⁄ or diar-
rhoea. In the absence of treatment, kidney
damage, meningitis, liver failure or death can
occur [3,4]. Treatment must be started as soon
as leptospirosis is suspected, i.e., before conﬁr-
mation of the diagnosis by laboratory tests.
Despite progress in treatment and intensive
supportive care, leptospirosis remains a poten-
tially fatal disease. Indeed, 20% of subjects
develop jaundice, and 5–10% die [4,5]. Conse-
quently, vaccination remains important for the
prevention of this disease, particularly for
exposed populations.
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Rodents, especially rats, are the predominant
reservoir of the disease. However, many other
wild or domestic animals (e.g., dogs, cats, cattle,
pigs, horses) can harbour the responsible micro-
organisms. The bacterium is transmitted either
directly from an infected animal or, more fre-
quently, by contact with freshwater, soil or food
contaminated by infected urine. Infection occurs
through skin abrasions or cuts, or through the
mucous membranes of the mouth or eyes [5,6]. For
many years, leptospirosis has been considered to
be an occupational infectious disease, and has
been recognised as a particular risk for those in
exposed professions, mainly sewage, pisciculture
or agriculture workers. However, freshwater leis-
ure activities now represent the predominant
sources of contamination in developed countries.
A recent case-control study in France showed that
the main risk-factors were contact with wild
rodents, contact with freshwater for professional
reasons, the presence of wounds, and canoeing or
kayaking [7].
In France, cases of leptospirosis are recorded by
the National Reference Centre for Leptospirosis at
the Pasteur Institute, Paris. In 2002, the incidence
of leptospirosis was estimated to be 0.61 ⁄ 100 000
inhabitants (365 cases), similar to the number of
new cases reported between 1994 and 2000, which
ranged from a minimum of 255 to a maximum of
434 in 1996 [8]. Among these cases, the most
prevalent serogroup was Icterohaemorrhagiae,
with a mean incidence rate of 0.20 cases ⁄ 105
population from 1987 to date [9]. However, the
incidence of the disease is probably underesti-
mated, because reporting is not mandatory.
Because of the permanent risk of contamination
for members of certain professions working in
places infested naturally by rodents, the Pasteur
Institute developed an anti-leptospiral vaccine,
intended originally for the sewer workers of Paris,
in 1974. The most severe forms of leptospirosis are
often caused by strains belonging to the Ictero-
haemorrhagiae serogroup and, consequently, the
French vaccine Spirolept (formerly named Lepto-
spires), which has been marketed since 1979, is
composed of an inactivated strain belonging to
this group. Clinical trials have demonstrated the
efﬁcacy of the vaccine and the high seroconver-
sion rate generated (95–100%) [10–12]. Moreover,
the vaccine is well-tolerated [13,14]. At present,
vaccination is recommended in France for
individuals who, because of their employment,
are in contact with contaminated water or
animals [15].
Although the summary of the product charac-
teristics of the anti-leptospiral vaccine speciﬁes a
subcutaneous (SC) route of infection, occupa-
tional physicians have often injected it via the
intramuscular (IM) route. Therefore, the main
objective of the present study was to compare the
safety of the SC and the IM routes in a placebo-
controlled randomised trial lasting 2.5 years.
Immunogenicity data obtained for the two routes,
assessed with new and more sensitive serological
tests, were also compared.
SUBJECTS AND METHODS
Criteria for selection of volunteers
Adults (aged 18–40 years) of either gender, weight > 55 kg for
men and >50 kg for women, with a body mass index of
17–27 kg ⁄m2, who were in good health (as assessed by a
complete physical examination, medical history, and biological
and serological tests) were eligible for this study. Exclusion
criteria were: (a) a known history of hepatitis B or C;
(b) positive serology for human immunodeﬁciency virus-1 or
-2, hepatitis B virus surface antigen, anti-hepatitis B virus core
antibodies and anti-hepatitis C virus antibodies; (c) acute or
chronic hepatic insufﬁciency; (d) acute or chronic renal
insufﬁciency; (e) risk of occupational exposure to leptospires,
including sewer system workers, garbage collectors, veteri-
narians, farmers and butchers; (f) participation in ‘at-risk’
sports, e.g., freshwater ﬁshing, hunting and caving; (g) any
vaccination during the 3-week period preceding inclusion; (h)
scheduled vaccination or booster vaccination required in the 7-
month period after the ﬁrst injection of the anti-leptospiral
vaccine; (i) consumption of non-steroidal anti-inﬂammatory
drugs, corticosteroids or immunosuppressants during the
month preceding anti-leptospiral vaccination; (j) a foreseen
requirement for medication during the study, or the use of
prescription drugs during the 4-week period preceding inclu-
sion; (k) intake of non-prescription medication during the
2-week period preceding inclusion; (l) a history of drug abuse
or alcoholism; (m) a history of atopy or allergy to drugs; (n) a
condition that might recur during or immediately after the
study; and (o) women without effective contraception.
Study design
A double-blind, randomised, placebo-controlled, parallel-
group study was designed to assess the safety and immuno-
genicity of the anti-leptospiral vaccine (four successive
injections on day 0, day 14, month 6 and month 30) admin-
istered subcutaneously or intramuscularly (Fig. 1). The study
was conducted in a single centre.
The volunteers (n = 84) were randomised into four groups
according to the product (vaccine or placebo), the injection
route (SC or IM) and the injection site (deltoid muscle of either
right or left arm), all of which remained the same throughout
the study, as follows: SC vaccine, n = 30; IM vaccine, n = 30;
SC placebo, n = 12; and IM placebo, n = 12. To avoid any bias,
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the investigator was not informed of the injection route. Only
the nurse, who was independent of the study, knew the route
of injection. Participants did not know the nature of the
product (placebo or vaccine) injected.
All volunteers were followed for 30 months and, for those
in the SC and IM vaccine groups, a fourth vaccine dose was
injected at month 30, with a follow-up visit at month 31.
This extension of the study was decided after the onset of
the trial in order to gather additional information concerning
the tolerance and immunogenic properties of the anti-
leptospiral vaccine. Fifty-four subjects received the fourth
vaccination: 26 (16 males and ten females) in the IM vaccine
group, and 28 (21 males and seven females) in the SC
vaccine group.
Use of aspirin, non-steroidal anti-inﬂammatory drugs,
corticosteroids or immunosuppressants was prohibited within
the 1-month period following each injection.
The study was conducted according to the Declaration of
Helsinski and French law for biomedical research. The proto-
col was approved by the Consulting Committee for the
Protection of Persons Participating in Biomedical Research
(CCPPRB) of Auvergne (Clermont-Ferrand). Written informed
consent was obtained from each volunteer.
Vaccine and placebo
The anti-leptospire vaccine was manufactured by Thea Labor-
atories (Clermont-Ferrand, France; batch no. 98G13 for day 0,
day 14 and month 6 injections, and batch no. 00K30 for the
month 30 injection). Each package contained a single-use glass
syringe with a 1-mL dose of vaccine. Each syringe contained
2 · 108 leptospira from the Icterohaemorrhagiae serogroup,
inactivated with formaldehyde and puriﬁed, together with
sodium mercurothiolate (0.008 mg ⁄ syringe) as a preservative,
in phosphate-buffered saline. The placebo (vehicle alone) was
prepared and packaged to resemble the vaccine (batch no.
B7470).
Evaluation of safety
Within the 1-h period following injection, and for 3 days after
each injection (i.e., day 3, day 17, month 6+3 days and month
30+3 days), the occurrence of any local reaction at the injection
site, deﬁned as pain, redness, oedema, induration, ecchymosis
or others, was recorded. Systemic reactions were also
recorded, according to a deﬁned list, i.e., asthenia, headache,
arthralgia, myalgia, chills, sweating, malaise, fever ‡38C, or
others.
The volunteers measured their body temperature twice-
daily using an oral thermometer during the 3-day period
following each of the four (day 0, day 14, month 6 and month
30) injections and recorded the values in a diary.
Adverse events were reported at each follow-up visit.
Laboratory tests, performed at selection and day 0, day 14,
week 6, month 6, month 7, month 30 and month 31, were:
white blood cell count; platelet count; urea; creatinaemia; and
serum transaminases (alanine aminotransferase and aspartate
aminotransferase). Female subjects gave urine samples for a
pregnancy test before each injection.
Serological assays
Blood was drawn for serological assays at the following times:
days 0 and 14, week 6, and months 6, 7, 12, 18, 24, 30 and 31.
Samples were analysed by KIT Biomedical Research (Royal
Tropical Institute, Amsterdam, The Netherlands).
Microscopic agglutination tests (MATs) were performed
by incubating serial dilutions of the serum samples with an
equal volume of a culture of strain Verdun (serogroup
Icterohaemorrhagiae, serovar icterohaemorrhagiae) at 30C
for 2–4 h. Agglutination was evaluated under dark-ﬁeld
microscopy. The titre of each sample was deﬁned as the
dilution giving 50% agglutination, i.e., leaving 50% of the
cells unagglutinated.
IgM and IgG ELISAs were performed using antigen
prepared from 28-day cultures of the strain Verdun. The
bacteria were grown in modiﬁed EMJH medium and harvest-
ed at an optical density (OD) corresponding to 6 · 108
leptospira ⁄mL. Cultures were harvested by centrifugation at
2800 g for 60 min and the pellet was suspended in phosphate-
buffered saline (pH 7.2). Antigen was prepared by heating the
suspension at 100C for 90 min, followed by sonication at
100 W for 60 s and centrifugation at 17 700 g to remove cell
debris. A 1:200 dilution of the supernatant, corresponding to
2.4 · 107 leptospira ⁄mL, was used to coat the plates by
incubation at 4C for 18 h. The plates were then post-coated
with StabilCoat (SurModics, Eden Prairie, MN, USA). For
antibody detection, sera were centrifuged and diluted 1:100 in
phosphate-buffered saline (pH 7.2) containing Tween-20 0.1%
v ⁄v and normal goat serum 10% w ⁄v. After incubation with
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Fig. 1. Overview of double-blind study of local and systemic tolerance and immunogenicity following subcutaneous (SC)
and intramuscular (IM) injection of inactivated anti-leptospiral vaccine in healthy volunteers in four randomised parallel
groups (SC vaccine, IM vaccine, SC placebo, and IM placebo). D, day; W, week; M, month.
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horseradish peroxidase-conjugated anti-human IgM or IgG,
diluted 1:3000, the reaction was developed with tetramethyl-
benzine. The chromogenic reaction was stopped by the
addition of 0.5 M H2SO4 and the OD was measured at 450 nM.
The cut-off OD450 nm values (mean OD + 3.09 SD) for
ELISA, based on samples of sera collected from 100 French
blood donors, were 0.207 for the IgM ELISA (mean OD, 0.065;
SD 0.046) and 0.071 for the IgG ELISA (mean OD, 0.012;
SD 0.019). IgM and IgG ELISA values were then expressed as
ODs relative to these respective thresholds. The subject was
considered to have seroconverted when the relative OD value
(OD value ⁄ cut-off OD450 nm) was ‡1. The sensitivity, speciﬁcity
and selectivity of the IgM and IgG ELISAs were calculated
based on the results for 39 samples collected >9 days after
onset of the disease from patients with conﬁrmed leptospiro-
sis, 100 samples from healthy donors, and 157 samples from
patients with various illnesses other than leptospirosis, and
were 94.3%, 99.0% and 99.4%, respectively, for the IgM
ELISA, and 74.3%, 98.0% and 98.1%, respectively, for the IgG
ELISA. The cut-off level for agglutinating antibodies was taken
to be 1:20, and a reciprocal ‡20 was considered to be positive.
The sensitivity, speciﬁcity and selectivity of the MAT were
94.7%, 100% and 100%, respectively.
Statistical analyses
Tolerance was assessed using a modiﬁed intent-to-treat ana-
lysis; volunteers who received at least one injection were
included. Safety was assessed by using the chi-square test (or
Fisher’s exact test) to compare the number of subjects in the IM
and SC vaccine groups who had at least one local reaction or
deﬁned systemic reaction within 1 h or 3 days of an injection,
or during follow-up between injections. Differences in the
strength of the immune response, assessed as the antibody
titres obtained, between the SC and IM vaccine groups were
investigated using the Mann–Whitney U-test. The difference in
the number of subjects with a positive immune response
between the two groups was investigated with the chi-square
test, with p £0.05 considered to be statistically signiﬁcant.
RESULTS
Eighty-four healthy volunteers, 58 men and 26
women, were recruited, with a mean ± SD age of
26 ± 6 years (range, 18–39 years), a mean weight
of 69.3 ± 9.5 kg (range, 49.8–86.0 kg), and a mean
body mass index of 23.1 ± 2.5 kg ⁄m2 (range,
17–27 kg ⁄m2). The four randomisation groups
were comparable with respect to these demo-
graphical data.
All except three volunteers received the day 0,
day 14 and month 6 injections. Participation was
discontinued for one volunteer in the SC placebo
group, who withdrew from the study because of
an unrelated serious adverse event (Meniere’s
disease), and for two volunteers in the IM vaccine
group, who changed residence and were lost to
follow-up. The remaining discontinuations before
the month 30 injection were: one subject in the IM
placebo group who became pregnant during the
month 12–14 interval; three subjects (two in the
SC placebo group and one in the SC vaccine
group) who were lost to follow-up following a
change of residence; and one subject in the IM
vaccine group who withdrew consent for perso-
nal reasons.
Local reaction rates were comparable for the SC
and IM vaccine groups within 1 h of each injec-
tion and no systemic reactions were observed
(Table 1). No signiﬁcant difference was noted
between the two vaccine groups within the 3-day
period following the ﬁrst injection. However, for
the day 14, month 6 and month 30 injections, the
number of subjects with at least one deﬁned local
reaction was signiﬁcantly higher in the SC vaccine
group than in the IM vaccine group (Table 1).
Systemic reactions within 3 days were rare and
the SC and IM vaccine groups did not differ. No
local reactions were reported during the follow-
up (between-injection intervals). Systemic adverse
events were rare and were deemed by the
investigator to be independent of the trial inter-
vention (Table 2). One clinically signiﬁcant sys-
temic adverse event that occurred in the SC
vaccine group involved hepatocellular damage,
with moderate increases in alanine aminotrans-
ferase and aspartate aminotransferase at the
month 6 and 7 visits that returned spontaneously
to normal. This subject was concomitantly taking
Nureﬂex (ibuprofen), a non-steroidal anti-inﬂam-
matory drug known to induce transient rises in
transaminases. Other reported adverse events
were most frequently gastrointestinal, musculo-
skeletal, skin or general disorders.
On day 0, ﬁve subjects had speciﬁc antibody
titres slightly above the cut-off value for
either IgM or IgG: one (3.3%) for IgM in the
SC vaccine group; one (3.3%) for IgG in the SC
vaccine group; two (7.1%) for IgG in the IM
vaccine group; and one (8.3%) for IgG in the IM
placebo group. On day 0, mean absolute OD
values were all below the cut-off values of 0.207
for IgM and 0.071 for IgG, whereas these values
for the placebo (SC and IM) and vaccine
(SC and IM) groups were: for IgM, 0.039 ± 0.03,
0.039 ± 0.02, 0.061 ± 0.06, and 0.046 ± 0.03,
respectively; and for IgG, 0.024 ± 0.01, 0.028 ±
0.02, 0.030 ± 0.02 and 0.031 ± 0.03, respectively.
None of the samples collected at day 0 agglu-
tinated in the MAT. None of the individuals from
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the placebo groups mounted an immune response
above baseline values in any of the three serolog-
ical assays (IgM, IgG and MAT) at any time-point.
A strong IgM response was observed after the
ﬁrst injection; thus, on day 14, speciﬁc IgM levels
had risen over ten-fold, compared with pre-
immune levels, in both the SC and IM vaccine
groups, with respective IgM seroconversion rates
of 93% (95% CI 77–99%) and 97% (95% CI 81–
100%) (Table 3). As expected, speciﬁc IgG levels
on day 14 for the SC and IM groups were about
ﬁve-fold higher than pre-immune levels, with
respective IgG seroconversion rates of 67%
(95% CI 47–82%) and 53% (95% CI 35–71%).
On day 14, agglutinating antibody titres for the
majority of the subjects in the vaccine groups did
not exceed the cut-off value, and seroconversion
rates for the SC and IM vaccine groups were 20%
(95% CI 8–39%) and 13% (95% CI 4–32%),
respectively. On day 14, mean absolute OD values
for the SC and IM vaccine groups were
0.982 ± 0.55 and 0.944 ± 0.60, respectively, for
IgM, and 0.157 ± 0.22 and 0.167 ± 0.25, respect-
ively, for IgG. No further increases in speciﬁc IgM
and IgG antibody levels were observed in
response to the second challenge, which was
administered at day 14 and measured at week 6.
Agglutinating antibody titres increased transi-
ently after the second challenge.
The third challenge at month 6 (ﬁrst booster)
induced marked increases in IgM, IgG and agglu-
tinating antibody levels. Seroconversion rates
were highest for IgG, reaching 97% (95% CI 80–
100%) for the SC route, and 96% (95% CI 80–
100%) for the IM route, followed closely by the
seroconversion rates for agglutinating antibodies,
Table 2. Systemic adverse events during follow-up
between injectionsa in healthy volunteers receiving sub-
cutaneous (SC) or intramuscular (IM) injections of inacti-
vated anti-leptospiral vaccine or placebo according to
vaccination schedule
Follow-up periodb
Number (%) of subjects with at least one systemic
adverse eventa
Vaccine group Placebo group
SC IM SC IM
D0+3 days–D14 n = 30
c
2 (6)
n = 30
1 (3)
n = 12
0
n = 12
1 (8)
D14+3 days–M6 n = 28
0
n = 30
0
n = 12
1 (8)
n = 12
0
M6+3 days–M30 n = 29
8 (28)
n = 28
11 (39)
n = 12
2 (17)
n = 11
7 (64)
M30+3 days–M31 n = 26
2 (8)
n = 28
1 (4)
NA
NA
NA
NA
NA, not applicable (volunteers in placebo groups did not receive the fourth
injection).
aExcluding the 3 days post-injection reported in Table 1.
bVolunteers were followed after each of the four injections at day 0, day 14, month 6
and month 30.
cn is the number of subjects with complete follow-up during the period under
consideration.
Table 1. Local and systemic reac-
tions within 1 h or 3 days of each
subcutaneous (SC) or intramuscular
(IM) injection of inactivated anti-
leptospiral vaccine or placebo into
healthy volunteers in four random-
ised groups
Type of reaction Injection time
No. (%) of subjects with at least one deﬁned reaction
Vaccine group Placebo group
SC
(n = 30)
IM
(n = 30)
pa SC
(n = 12)
IM
(n = 12)
Local reaction
Within 1 h D0 1 (3) 0 1.0 0 0
D14 0 1 (3) 1.0 0 0
M6 1 (3) 0b 1.0 1 (9)c 0
M30 5 (18)b 0d 0.052 NA NA
Within 3 days D0 12 (40) 6 (20) 0.091 1 (8) 0
D14 12 (40) 4 (13) 0.0195 2 (17) 1 (8)
M6 18 (60) 5 (18)b 0.01 1 (9)c 1 (8)
M30 14 (50)b 4 (15)d 0.007 NA NA
Systemic reaction
Within 1 h D0 0 0 1.0 0 0
D14 0 0 1.0 0 0
M6 0 0b 1.0 0c 0
M30 0b 0d 1.0 NA NA
Within 3 days D0 1 (3) 4 (13) 0.35 3 (25) 0
D14 1 (3) 1 (3) 1.0 0 0
M6 0 3 (11)b 0.11 0c 1 (8)
M30 1 (4)b 0d 1.0 NA NA
NA, not applicable (volunteers in placebo groups did not receive the fourth injection); D0, day 0; D14, day 14; M6,
month 6; M30, month 30.
aSC vs. IM; chi-square test or Fisher’s exact test.
bn = 28.
cn = 11.
dn = 26.
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with 97% (95% CI 80–100%) for the SC route and
86% (95% CI 66–95%) for the IM route, and for
IgM, with 86% (95% CI 67–96%) for the SC route,
and 75% (95% CI 55–89%) for the IM route.
In response to the fourth challenge at month
30 (second booster), IgM, IgG and agglutinating
antibody levels at month 31 all increased
sharply. Increases in IgG and agglutinating
antibody titre were much more pronounced than
the responses to previous challenges, while the
increase in the IgM antibodies was similar to that
observed in response to the ﬁrst challenge. At
month 31, mean absolute OD (±SD) values for
the SC and IM vaccine groups were 0.771 ± 0.56
and 0.803 ± 0.60, respectively, for IgM, and
1.737 ± 0.84 and 1.281 ± 0.75, respectively, for
IgG. Median reciprocal MAT titres rose to 320
(25–75 percentiles, 160–640) in the SC vaccine
group, and to 240 (25–75 percentiles, 160–400) in
the IM vaccine group. The SC and IM vaccine
groups achieved 100% seroconversion for IgG
after the second boost.
Starting at day 14 after the ﬁrst challenge,
speciﬁc IgM and IgG levels were increased signi-
ﬁcantly (p <0.001) in the vaccine groups com-
pared with the placebo group, and this difference
remained throughout the study period. The
increase in speciﬁc agglutinating antibody levels
was statistically signiﬁcant (p <0.001) from week
6 after the second challenge.
Except for signiﬁcantly (p 0.04) higher IgG
levels in the SC vaccine group at month 31, no
difference in the immune response was observed
at the different time-points between the SC and
IM vaccine groups (Fig. 2) and seroconversion
rates were identical (Table 3).
DISCUSSION
This study on the safety and immunogenicity of
an anti-leptospiral vaccine compared the SC and
IM administration routes. Local and systemic
reactions were searched for systematically at
deﬁned times and during follow-up between
injections. Reactions at the injection site were rare
within 1 h of injection, but local reactions differed
signiﬁcantly according to the injection route
within 3 days, with 40–60% and 13–20% for
subjects injected subcutaneously and intramuscu-
larly, respectively, being affected. No systemic
reactions occurred within 1 h of injection, and
systemic reactions were rare within 3 days of
injection (0–4% and 0–13% for the SC and IM
routes, respectively).
In a previous study, lower rates of adverse
events following injection of inactivated anti-
leptospiral vaccine were reported. Thus, among
454 subjects who received vaccine, only three
(0.66%) had general reactions (nausea) and seven
(1.5%) had local reactions (redness or oedema)
Table 3. Seroconversion in a double-blind randomised study of healthy volunteers injected subcutaneously or
intramuscularly with inactivated anti-leptospiral vaccine
Time
Numbers and proportions of subjects who seroconverteda
Microscopic agglutination test IgM ELISA IgG ELISA
SC
(%)
IM
(%) p
SC
(%)
IM
(%) p
SC
(%)
IM
(%) p
D0b 0 (0) 0 (0) NA 1 (3) 0 (0) 0.31 1 (3) 2 (7) 0.55
D14b 6 (20) 4 (13) 0.49 28 (93) 29 (97) 0.55 20 (67) 16 (53) 0.43
W6 17 (57) 23 (77) 0.10 28 (93) 27 (90) 0.69 16 (53) 19 (63) 0.43
M6b 10 (33) 12 (43)d 0.46 15 (50) 10 (36)d 0.27 14 (47) 15 (50)d 0.80
M7 28 (97)c 24 (86)d 0.15 25 (86)c 21 (75)d 0.28 28 (97)c 27 (96)d 0.98
M12 20 (69)c 21 (77)e 0.93 10 (31)c 11 (39)d 0.87 26 (90)c 24 (86)d 0.65
M18 16 (57)d 11 (41)e 0.22 8 (29)d 7 (26)e 0.83 23 (83)d 21 (78)e 0.69
M24 10 (34)c 10 (37)e 0.84 6 (21)c 3 (11)e 0.33 19 (66)c 17 (63)e 0.84
M30b 6 (21)c 5 (18)e 0.84 6 (21)c 4 (15)e 0.84 15 (52)c 12 (44)e 0.59
M31 27 (96)d 25 (96)f 0.96 27 (93)c 25 (96)f 0.51 29 (100)c 26 (100)f NA
NA, not applicable; D, day; M, month; SC, subcutaneous; IM, intramuscular; D0, day 0; D14, day 14; W6, week 6; M6, month 6; M7, month 7; M12, month 12; M18, month 18;
M24, month 24; M30, month 30; M31, month 31.
aIgM and IgG ELISA results were expressed as OD450 nm absorbance values relative to cut-off values of 0.207 and 0.071, respectively. Seroconversion was deﬁned as a relative
OD value ‡1. The cut-off level of agglutinating antibodies determined in the microscopic agglutination test was taken to be 1:20, and a reciprocal titre ‡20 was considered to be
positive.
bVisit with vaccination.
cn = 29.
dn = 28.
en = 27.
fn = 26.
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[10–12]. However, the study was performed
>20 years ago, at which time clinical studies did
not meet the same standards as those required
now. A more recent study from 1997 evaluated
the tolerance of 50 canal workers to anti-leptospi-
ral vaccine, and concluded that the most import-
ant clinical symptoms were erythema and
indurations exceeding 10 mm in 6% of the sub-
jects [13]. The overall tolerance to the anti-lepto-
spiral vaccine was considered to be good, or very
good, by 97.7% of the 85 occupational physicians
who took part in the evaluation [14]. All of these
results are in agreement with other reports of
good tolerance and only low-grade local reactions
with other inactivated leptospirosis vaccines
[16,17].
Comparison with other vaccines used routinely
in adults indicates that the local and general
tolerance to the anti-leptospiral vaccine may be
considered as acceptable. Indeed, tetanus or
diphtheria–tetanus vaccines, which are com-
monly considered to be vaccines with good local
and general tolerance, produce local reactions in
up to 10% of recipients, while 10% develop fever,
and 5% experience irritability, malaise or other
symptoms; in addition, 50–85% of recipients may
have local reactions after booster doses [18].
Local reactions after anti-leptospiral vaccine
injection were signiﬁcantly more frequent for the
SC than for the IM route. Other studies compar-
ing the IM and SC routes of administration of
various vaccines have also concluded that SC
injections generate signiﬁcantly more local
reactions [19,20] (http://www.who.int/vaccines-
documents/DocsPDF00/www562.pdf). A study
investigating the inﬂuence of needle length on
the local reaction following routine immunisa-
tion with common vaccines revealed that local
reactions were less frequent with a long needle.
It was hypothesised that the muscle was reached
more easily with a long needle [21]. The reasons
for the different frequencies of local reactions
observed in the SC and IM groups are not clear.
Local inﬂammation could be explained by par-
ticipation of the immune system and the inﬂam-
matory cells located in the skin and deep dermis.
Alternatively, local reactions may also occur in
muscle, but are more frequently clinically silent
because of the depth.
Analyses of immunisations against other path-
ogens gave the same rates of seroconversion for
the SC and IM routes, thereby suggesting that the
immune system was challenged in a similar
manner. The efﬁcacy of the vaccine and the high
seroconversion rate observed after vaccination
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Fig. 2. Kinetics of anti-Leptospira interrogans serogroup
Icterohaemorrhagiae antibody responses (IgG, IgM and
agglutinating antibodies) following successive injections of
anti-leptospire vaccine. Volunteers were injected subcuta-
neously or intramuscularly with inactivated and puriﬁed
leptospires (2 · 108 L. interogans serogroup Icterohaemor-
rhagiae) or placebo: day 0, day 14, month 6 and month 30
(vertical arrows). Speciﬁc IgM (upper panel) and IgG
(middle panel), measured by ELISA, are expressed as
mean OD450 nm values relative to cut-off values of 0.207
and 0.071, respectively. Agglutinating antibodies were
measured using the microscopic agglutination test (MAT;
lower panel) and their cut-off level was taken to be 1:20,
with a reciprocal titre ‡20 being considered positive.
(*p <0.05, SC vs. IM routes). SC, subcutaneous; IM,
intramuscular; OD, optical density.
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(95–100%) in previous studies with this anti-
leptospiral vaccine [10–12] were conﬁrmed by this
clinical trial. In the present study, the serocon-
version rates after the ﬁrst challenge were highest
for IgM, reaching 93% for the SC route and 97%
for the IM route. Seroconversion rates for IgG
after the ﬁrst booster were 97% for the SC route
and 96% for the IM route, and reached 100% after
the second booster dose. The immune responses
mounted by the volunteers were characterised by
the strongest IgM response following the primary
vaccination, and strong IgG and agglutinating
antibody responses, accompanied by the expected
diminution of IgM, following the third and fourth
doses administered at month 6 and month 30,
respectively. The only immune response seen
after the second injection was an increase in
agglutinating antibodies. As expected, the third
and fourth doses (ﬁrst and second boosters) had
much stronger effects than the primary vaccin-
ation on IgG and agglutinating antibody levels.
Median agglutinating antibody levels of 1:320 and
1:240 were induced at month 31 in response to
vaccination by both the SC and IM routes, with
96% of subjects showing seroconversion by both
routes. Relatively low agglutinating antibody
levels were also observed in an earlier study
using a different vaccine [22]. Animal studies
have shown that good protection is achieved with
low titres [23].
The antibody responses after SC or IM injection
of this anti-leptospiral vaccine showed a very
similar evolution, except for a slightly, but statis-
tically signiﬁcantly, stronger IgG response after
the fourth SC challenge at month 31; 1 month
after the second booster injection, mean IgG levels
were 58-fold and 39-fold higher than pre-immune
values following SC and IM vaccination, respect-
ively. These strong and speciﬁc antibody re-
sponses measured at month 31, 2 years after the
primary vaccination, show that immunological
memory was maintained during this period.
The results of this prospective clinical trial
conﬁrm the good safety proﬁle of the anti-lepto-
spiral vaccine, and suggest that IM administration
induces fewer local reactions than the SC route. In
addition, the good immunogenicity of the vaccine
was conﬁrmed and the monitoring of antibody
levels demonstrated that a booster injection is
accompanied by a very strong antibody response
and a 100% seroconversion rate at month 30 after
primary vaccination.
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